The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis. Thirty children aged 1-15 years with acute lymphoblastic leukaemia received 'intensification modules' according to the MRC United Kingdom acute lymphoblastic leukaemia regimen UKALL XI. This contains the moderately emetogenic drugs daunorubicin, etoposide, and cytarabine. Fifteen children received an intravenous loading dose of ondansetron followed by intravenous or oral doses 12 hourly for five days. Fifteen children received intravenous metoclopramide every six hours for three days with a loading dose of dexamethasone, repeated every eight hours for three days intravenously or orally. Efficacy was assessed by a diary card documenting the incidence of nausea, retching, or vomiting. In the 24 hour period after starting chemotherapy, ondansetron was more effective, with a complete or major response rate of 93%, compared with 330/o using metoclopramide/dexamethasone. (Arch Dis Child 1995; 73: 243-245) Keywords: chemotherapy, anti-emetic, leukaemia. Because oftheir cost, however, there has been an understandable reluctance to use them more widely for moderately emetogenic regimens, particularly since their superiority over other combinations has been less clear in adult studies.12 In the present study we selected a chemotherapy regimen commonly used in children to document the incidence of vomiting and nausea where our standard antiemetic treatment was given and to determine whether better results could be obtained with ondansetron. The goal was to abolish emesis completely, challenging the assumption that this was not possible without unacceptable toxicity.
Paediatric Department, Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT G S Dick S T Meller C R Pinkerton Patients were required to meet the following study criteria: they had not experienced uncontrollable nausea and vomiting on previous treatments, and they had no other serious illnesses, no other antiemetic administration, no nausea and vomiting before the treatment was given, no concurrent benzodiazepines, no cerebral metastases or meningeal leukaemia, and no previous hypersensitivity or lack of efficacy with ondansetron or metoclopramide.
A full blood count, electrolyte estimation, creatinine, and liver function tests were performed before treatment. Details of previous chemotherapy courses and episodes of nausea or vomiting were documented.
Of the 30 patients studied, 25 were receiving the early intensification module and of these, seven had previously received daunorubicin Dick, Meller, Pinkerton (figure). One patient aged 18 months randomised to ondansetron was difficult to assess as he vomited only with coughing. The ondansetron was changed to six hourly in an effort to control the emesis but he continued to vomit when coughing. Of the 15 children randomised to metoclopramide/dexamethasone 10 were changed to ondansetron during the first 24 hours. All responded to this change. One patient was changed following her second administration of intravenous metoclopramide when she felt very unwell and agitated. A second child was changed because of behaviourial disturbances after each of two doses.
Previous daunorubicin exposure did not appear to affect the results. Five patients randomised to ondansetron and seven patients randomised to received metoclopramide/dexamethasone were previously exposed to daunorubicin. In these patients emesis was well controlled with ondansetron but efficacy was only apparent in one patient who received metoclopramide/dexamethasone.
Delayed emesis or nausea (on days 6-11) occurred in seven patients. Four had initially received ondansetron and three metoclopramide. One had been changed from metoclopramide to ondansetron. In all cases these symptoms were mild.
'Other symptoms' documented were stomach pains in two patients and tiredness in Table 4 Details of randomisation, early/late intensification, and response to study antiemetics one patient receiving metoclopramide/dexamethasone, and leg pains in one patient receiving ondansetron.
The appetite grading was consistent with the overall results of the study. Of the patients randomised to ondansetron, 90% recorded 'as usual' or 'better than usual', whereas of the patients randomised to metoclopramide/ dexamethasone, 87% recorded either 'worse than usual' or 'very poor'.
Discussion
This study shows that ondansetron given as an initial dose followed by 12 hourly intravenous and/or oral dosing is sufficient to achieve 93% efficacy in controlling emesis induced by combination chemotherapy in patients receiving treatment for acute lymphoblastic leukaemia.
Since daunorubicin was excluded from the UKALL XI induction regimen, patients do not usually experience vomiting during this initial phase of treatment. With the use of ondansetron it should now be possible for the majority of these children to complete their chemotherapy protocol with complete or major control of emesis. This would make admission to hospital less traumatic and the whole concept of leukaemia treatment less daunting for parents.
Financial restraints in the present economic climate may influence or restrain the use of certain drugs and the more effective agents may be limited to regimens regarded as 'highly' emetogenic. While all of the 5HT3 antagonists are certainly expensive they are probably costeffective.
On the study schedule described, ondansetron is given twice a day, whereas metoclopramide and procyclidine are given four times a day and dexamethasone three times a day. If these agents are given intravenously the cost of disposable equipment must be accounted for, as well as the potential costs and nursing time imposed by the vomiting patient. Moreover, our current practice is to start with a single daily dose of ondansetron during chemotherapy and increase to 12 hourly only if the single dose is ineffectve.
Access to a vein, by either a Hickman line, a central line, or a cannula, is a potential infection risk and is distressing to some children. Therefore, if an intravenous route has been chosen for antiemetic administration, the less such access is required the greater the potential benefit for the patient. Administration of metoclopramide with dexamethasone requires access on possibly six occasions each day, whereas ondansetron requires access only twice.
In adult studies 5HT3 antagonists have shown benefit with the more emetogenic (cisplatin based) regimens and they are therefore often reserved for second line use after failure of other antiemetics. Anticipatory vomiting develops readily in children and is very difficult to treat; therefore it is important to obtain antiemetic control in the initial stages.'3 The number of patients recruited to this study was small but the marked difference in efficacy in a regimen classified as moderately emetogenic is significant.
With the advent of 5HT3 antagonists, particularly in combination with dexamethasone,14 it is no longer acceptable for children to be lethargic, unwell with nausea and vomiting, or at risk from extrapyramidal reactions when receiving treatment for leukaemia. The optimal route and schedule for ondansetron and the other 5HT3 antagonists remains to be determined in children and it is likely that shorter simpler schedules than used in this study may prove equally effective.
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